GJB2 | Gap junction protein, beta 2, 26kDa | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GJC3 | Gap junction protein, gamma 3, 30.2kDa | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GLRA1 | Glycine receptor, alpha 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Not detected |
GLRA2 | Glycine receptor, alpha 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
GLRA3 | Glycine receptor, alpha 3 | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Tissue enriched |
GLRB | Glycine receptor, beta | Disease related genes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
GNLY | Granulysin | Predicted intracellular proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
GRIA2 | Glutamate receptor, ionotropic, AMPA 2 | Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
GRIA3 | Glutamate receptor, ionotropic, AMPA 3 | Disease related genes Potential drug targets Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enhanced |
GRIK4 | Glutamate receptor, ionotropic, kainate 4 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GRIN1 | Glutamate receptor, ionotropic, N-methyl D-aspartate 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins Transporters
| | | | | Tissue enriched |
GRIN2C | Glutamate receptor, ionotropic, N-methyl D-aspartate 2C | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Group enriched |
HCN2 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 2 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
HCN4 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
HPX | Hemopexin | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
HSPA1A | Heat shock 70kDa protein 1A | Cancer-related genes Mitochondrial proteins Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
HSPA1B | Heat shock 70kDa protein 1B | Cancer-related genes Mitochondrial proteins Plasma proteins Predicted intracellular proteins Transporters
| | | | | Expressed in all |
HTN3 | Histatin 3 | Predicted secreted proteins Transporters
| | | | | Tissue enriched |
HTR3A | 5-hydroxytryptamine (serotonin) receptor 3A, ionotropic | FDA approved drug targets Predicted membrane proteins Transporters
| | | | | Group enriched |
HTR3D | 5-hydroxytryptamine (serotonin) receptor 3D, ionotropic | Predicted membrane proteins Transporters
| | | | | Not detected |
HVCN1 | Hydrogen voltage-gated channel 1 | Predicted intracellular proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ITPR1 | Inositol 1,4,5-trisphosphate receptor, type 1 | Disease related genes Plasma proteins Potential drug targets Predicted membrane proteins Transporters
| | | | | Mixed |
KCNA2 | Potassium voltage-gated channel, shaker-related subfamily, member 2 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNA3 | Potassium voltage-gated channel, shaker-related subfamily, member 3 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNA5 | Potassium voltage-gated channel, shaker-related subfamily, member 5 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNB1 | Potassium voltage-gated channel, Shab-related subfamily, member 1 | FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNC3 | Potassium voltage-gated channel, Shaw-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCND2 | Potassium voltage-gated channel, Shal-related subfamily, member 2 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCND3 | Potassium voltage-gated channel, Shal-related subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNF1 | Potassium voltage-gated channel, subfamily F, member 1 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNH2 | Potassium voltage-gated channel, subfamily H (eag-related), member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNH3 | Potassium voltage-gated channel, subfamily H (eag-related), member 3 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNJ1 | Potassium inwardly-rectifying channel, subfamily J, member 1 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ13 | Potassium inwardly-rectifying channel, subfamily J, member 13 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ16 | Potassium inwardly-rectifying channel, subfamily J, member 16 | Predicted intracellular proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNJ2 | Potassium inwardly-rectifying channel, subfamily J, member 2 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNJ3 | Potassium inwardly-rectifying channel, subfamily J, member 3 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNJ5 | Potassium inwardly-rectifying channel, subfamily J, member 5 | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNJ6 | Potassium inwardly-rectifying channel, subfamily J, member 6 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |
KCNJ8 | Potassium inwardly-rectifying channel, subfamily J, member 8 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK16 | Potassium channel, subfamily K, member 16 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNK17 | Potassium channel, subfamily K, member 17 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK3 | Potassium channel, subfamily K, member 3 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNK5 | Potassium channel, subfamily K, member 5 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNK6 | Potassium channel, subfamily K, member 6 | Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Mixed |
KCNN2 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNN4 | Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | FDA approved drug targets Predicted intracellular proteins Predicted membrane proteins Predicted secreted proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ1 | Potassium voltage-gated channel, KQT-like subfamily, member 1 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
KCNQ2 | Potassium voltage-gated channel, KQT-like subfamily, member 2 | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Group enriched |
KCNQ3 | Potassium voltage-gated channel, KQT-like subfamily, member 3 | Disease related genes FDA approved drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enriched |